Congressional investigations have concluded that BGI maintains close ties to both the Chinese Communist Party and the People’s Liberation Army, noting that China’s system blurs the boundary between commercial activity and state security requirements. U.S. defense analysts have also documented Chinese research into human-performance enhancement, population DNA harvesting and military biotechnology modeling—all areas that could benefit from the troves of data BGI collects.
Warner warned that the trajectory resembles Huawei’s rise in telecommunications. A decade ago, Huawei combined extensive state support with aggressive pricing to embed equipment in global 5G networks before many governments recognized the security implications. U.S. trade restrictions eventually banned the sale of sensitive technology to Huawei in 2019, but by then Chinese hardware had already shaped much of the world’s telecom backbone. The senator contends that if Washington does not act faster on biotechnology, it may face a similar scenario in which Chinese firms dominate critical infrastructure before countermeasures take effect.
To address the perceived gap, Warner is pressing intelligence agencies to devote more resources to commercial technology sectors such as biotechnology, semiconductors and artificial intelligence. He contends that a longstanding focus on foreign governments and conventional militaries has left analysts under-resourced to track corporate actors that operate globally yet remain closely aligned with Beijing. A recent example, he noted, was Semiconductor Manufacturing International Corporation’s production of a six-nanometer chip in spite of sweeping export controls, an achievement that surprised Washington and suggested the existing monitoring apparatus is insufficient.
Legislators have been working on the BIOSECURE Act, which would limit Chinese biotech companies’ operations inside the United States. Several U.S. hospitals and research centers collaborating with Chinese genomics firms have come under federal scrutiny, raising concerns within the medical community about losing access to research funding and sequencing services. BGI has responded that it complies with all applicable laws and does not obtain Americans’ personal data through its U.S. activities.
Representative John Moolenaar, the Republican chair of the House Select Committee on the Chinese Communist Party, echoed Warner’s warnings at the same conference, saying Beijing routinely employs excess capacity and below-market pricing to push competitors out of business. He characterized China as the United States’ foremost technological adversary even as policymakers emphasize the importance of stable diplomatic relations.
Imagem: Internet
Warner also pointed to strains within the long-standing “Five Eyes” intelligence-sharing alliance, which includes the United States, the United Kingdom, Canada, Australia and New Zealand. Partners in Europe and elsewhere, such as the Netherlands and France, have publicly expressed concern that U.S. intelligence products may be influenced by domestic political considerations. The senator argued that restoring trust within these alliances is essential to tracking China’s technological advances, which increasingly span disciplines from quantum computing to advanced genomics.
An additional front involves global standards bodies. For decades, the United States leveraged leadership in organizations that set technical rules for wireless networks, satellites and the internet. According to Warner, China now deploys large delegations of engineers to international forums to influence standards in ways that align with its industrial strategy and authoritarian governance model. Renewed American engagement, he said, is required to ensure that emerging protocols in biotechnology, AI and other fields reflect transparent and ethical principles.
Outside analysts share the assessment that genomic data has become a strategic asset. A study by the RAND Corporation highlights how large-scale DNA datasets can advance both personalized medicine and military capabilities, underscoring the dual-use nature of the technology. While the United States continues to debate the parameters of an effective response, lawmakers across party lines are converging on the view that earlier intervention is necessary to avoid repeating past missteps in other high-tech arenas.
As the BIOSECURE Act moves through Congress and intelligence agencies recalibrate their priorities, the question is whether policy makers can develop safeguards that protect personal privacy and national security without hindering legitimate scientific collaboration. For Warner and his allies, timely action on BGI has become a test case of Washington’s capacity to adapt to a world in which data—especially genetic data—is a critical component of geopolitical power.
Crédito da imagem: Getty Images
